Strauß, Arne

[["dc.bibliographiccitation.firstpage","640"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","BJU International"],["dc.bibliographiccitation.lastpage","644"],["dc.bibliographiccitation.volume","109"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Seeliger, Stephan"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Fuezesi, Laszlo"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Loertzer, Hagen"],["dc.date.accessioned","2018-11-07T09:13:52Z"],["dc.date.available","2018-11-07T09:13:52Z"],["dc.date.issued","2012"],["dc.identifier.doi","10.1111/j.1464-410X.2011.10916.x"],["dc.identifier.isi","000299945100030"],["dc.identifier.pmid","22313503"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27265"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1464-4096"],["dc.title","Surgery Illustrated - Focus on Details A three-step technique for umbilicoplasty in a patent urachus"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","339"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Journal of Molecular Medicine"],["dc.bibliographiccitation.lastpage","346"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Krahn, Lisa"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Brehm, Ralph"],["dc.contributor.author","Loertzer, Hagen"],["dc.date.accessioned","2018-11-07T09:28:47Z"],["dc.date.available","2018-11-07T09:28:47Z"],["dc.date.issued","2013"],["dc.description.abstract","The aim of this study was to elucidate whether the treatment of a prostate carcinoma cell line (LNCaP) and LNCaP-derived tumors with the histone deacetylase (HDAC) inhibitor valproate in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus resulted in synergistic effects on cell proliferation and tumor growth. LNCaP cells were treated with valproate, temsirolimus or a combination of both. The proliferation rates and the expression of key markers of tumorigenesis were evaluated. In in vivo experiments, LNCaP cells were implanted into immune-suppressed male nude mice. Mice were treated with valproate (per os), temsirolimus (intravenously) or with a combination of both. Tumor volumes were calculated and mRNA expression was quantified. The incubation of LNCaP cells with the combination of valproate and temsirolimus resulted in a decrease of cell proliferation with an additive effect of both drugs in comparison to the single treatment. In particular, the combined application of valproate and temsirolimus led to a significant upregulation of insulin-like growth factor-binding protein-3 (IGFBP-3), which mediates apoptosis and inhibits tumor cell proliferation. In the mouse model, we found no significant differences in tumor growth between the different treatment arms but immunohistological analyses showed that tumors treated with a combination of valproate and temsirolimus, but not with the single drugs alone, exhibited a significant lower proliferation capacity."],["dc.identifier.doi","10.3892/ijmm.2012.1221"],["dc.identifier.isi","000313858500009"],["dc.identifier.pmid","23292124"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30859"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Spandidos Publ Ltd"],["dc.relation.issn","1107-3756"],["dc.title","Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Walleck, Eiko"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2018-11-07T09:28:04Z"],["dc.date.available","2018-11-07T09:28:04Z"],["dc.date.issued","2013"],["dc.identifier.isi","000333679600131"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30688"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Analysis of putative resistance mechanisms in recent treatments targeting the androgen receptor in castration-resistant prostate cancer (CRPC)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1293"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Radiology"],["dc.bibliographiccitation.lastpage","1307"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Rücker, Gerta"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2019-08-05T10:33:02Z"],["dc.date.available","2019-08-05T10:33:02Z"],["dc.date.issued","2018"],["dc.description.abstract","Purpose To compare partial nephrectomy (PN), radiofrequency ablation (RFA), cryoablation (CRA) and microwave ablation (MWA) regarding oncologic, perioperative and functional outcomes. Material and methods The MEDLINE, EMBASE and COCHRANE libraries were searched for studies comparing PN, RFA, CRA or MWA and reporting on any-cause or cancer-specific mortality, local recurrence, complications or renal function. Network meta-analyses were performed. Results Forty-seven studies with 24,077 patients were included. Patients receiving RFA, CRA or MWA were older and had more comorbidities compared with PN. All-cause mortality was higher for CRA and RFA compared with PN (incidence rate ratio IRR = 2.58, IRR = 2.58, p < 0.001, respectively). No significant differences in cancer-specific mortality were evident. Local recurrence was higher for CRA, RFA and MWA compared with PN (IRR = 4.13, IRR = 1.79, IRR = 2.52, p < 0.05 respectively). A decline in renal function was less pronounced after RFA versus PN, CRA and MWA (mean difference in GFR MD = 6.49; MD = 5.82; MD = 10.89, p < 0.05 respectively). Conclusion Higher overall survival and local control of PN compared with ablative therapies did not translate into significantly better cancer-specific mortality. Most studies carried a high risk of bias by selecting younger and healthier patients for PN, which may drive superior survival and local control. Physicians should be aware of the lack of high-quality evidence and the potential benefits of ablative techniques for certain patients, including a superior complication profile and renal function preservation. Key Points • Patients selected for ablation of small renal masses are older and have more comorbidities compared with those undergoing partial nephrectomy. • Partial nephrectomy yields lower all-cause mortality, which is probably biased by patient selection and does not translate into prolonged cancer-free survival. • The decline of renal function is smallest after radiofrequency ablation for small renal masses."],["dc.identifier.doi","10.1007/s00330-018-5660-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62282"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0938-7994"],["dc.relation.issn","1432-1084"],["dc.title","Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","715"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International braz j urol"],["dc.bibliographiccitation.lastpage","722"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Seseke, Sandra"],["dc.contributor.author","Bierwirth, Silke"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Seseke, Florian"],["dc.date.accessioned","2018-11-07T11:09:29Z"],["dc.date.available","2018-11-07T11:09:29Z"],["dc.date.issued","2008"],["dc.description.abstract","Purpose. The optimal management of patients with clinical stage I non-seminomatous germ cell testicular cancer (NSGCT I) was considered controversial until the European Germ Cell Cancer Consensus Group determined unambiguous treatment strategies In order to assess the long-term outcome we evaluated the data of patients with NSGCT I. Materials and Methods In a retrospective evaluation, we included 52 patients with a mean age of 26 years (range 15-58) who were treated with different modalities at our department between 1989 and 2003. Mean follow-up was 5 9 years (range 2-14 years) After orchiectomy, 39 patients were treated with chemotherapy, 7 patients underwent retroperitoneal lymph node dissection and 6 men were managed using a surveillance strategy. Survival, recurrence rate and time of recurrence were evaluated. The histological staging and treatment modality was related to the relapse. Results Tumor specific overall mortality was 3.8%. The mortality and relapse rate of the surveillance strategy, retroperitoneal lymph node dissection and chemotherapy was 16 7% / 50%, 14.3% / 14 3% and 0% / 2 5% respectively. All relapsed patients in the surveillance group as well as in the RPLND group had at least one risk factor for developing metastatic disease Conclusions Following the European consensus on diagnosis and treatment of germ cell cancer in patients with NSGCT Stage I any treatment decision must be individually related to the patient according to prognostic factors and care capacity of the treating centre. In case of doubt, adjuvant chemotherapy should be the treatment of choice, as it provides the lowest risk of relapse or tumor related death."],["dc.identifier.isi","000207705700013"],["dc.identifier.pmid","19111076"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53018"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Brazilian Soc Urol"],["dc.relation.issn","1677-5538"],["dc.title","Long-term Clinical Outcome in Patients with Stage-I Nonseminomatous Germ Cell Cancer. A Critical Review of Own Treatment Modalities in a Retrospective Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2626"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Molecular Cancer Therapeutics"],["dc.bibliographiccitation.lastpage","2633"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Stettner, Mark"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Burfeind, Peter"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T10:58:18Z"],["dc.date.available","2018-11-07T10:58:18Z"],["dc.date.issued","2007"],["dc.description.abstract","In the prostate, estrogen receptor beta (ER beta), the preferred receptor for phytoestrogens, has features of a tumor suppressor. To investigate the mechanisms underlying the beneficial effects on prostate cancer of histone deacetylase inhibitor valproic acid (VPA) and phytoestrogen tectorigenin, we analyzed the expression of ER after tectorigenin or VPA treatment. For further functional analysis, we knocked down ER beta expression by RNA interference. LNCaP prostate cancer cells were treated with 5 mmol/L VPA or 100 mu mol/L tectorigenin and transfected with small interfering RNA (siRNA) against ER beta. Control transfections were done with luciferase (LUC) siRNA. Expression of ER beta was assessed by Western blot. mRNA expression was quantitated by real-time reverse transcription-PCR. Expression of ER beta mRNA and protein markedly increased after VPA or tectorigenin treatment. When ER beta was knocked down by siRNA, the expression of prostate-derived Ets factor, prostate-specific antigen, prostate cancer-specific indicator gene DD3(PCA3), insulin-like growth factor-1 receptor, the catalytic subunit of the telomerase, and ER beta was up-regulated and the tectorigenin effects were abrogated. ER beta levels were diminished in prostate cancer and loss of ER beta was associated with proliferation. Here, we show that siRNA-mediated knockdown of ER beta increases the expression of genes highly relevant to tumor cell proliferation. In addition, we show that one prominent result of treatment with VPA or tectorigenin is the up-regulation of ER beta resulting in antiproliferative effects. Thus, these drugs, by restoring the regulatory function of ER in tumor cells, could become useful in the intervention of prostate cancer."],["dc.identifier.doi","10.1158/1535-7163.MCT-07-0197"],["dc.identifier.isi","000250252100003"],["dc.identifier.pmid","17913855"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50445"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","1535-7163"],["dc.title","The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e16097"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","e16097"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Grünwald, Viktor"],["dc.contributor.author","Bergmann, Lothar"],["dc.contributor.author","Goebell, Peter J."],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Meiler, Johannes"],["dc.contributor.author","Hartmann, Arndt"],["dc.contributor.author","Bedke, Jens"],["dc.date.accessioned","2020-12-10T18:41:37Z"],["dc.date.available","2020-12-10T18:41:37Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.15_suppl.e16097"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77629"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAd001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study)."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","924"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Urology Focus"],["dc.bibliographiccitation.lastpage","936"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T14:23:51Z"],["dc.date.available","2020-12-10T14:23:51Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.euf.2017.08.007"],["dc.identifier.issn","2405-4569"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72062"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Gender-specific Differences in Recurrence of Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","272"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","280"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Grünwald, Viktor"],["dc.contributor.author","Hilser, Thomas"],["dc.contributor.author","Meiler, Johannes"],["dc.contributor.author","Goebell, Peter J."],["dc.contributor.author","Ivanyi, Philipp"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Hartmann, Arndt"],["dc.contributor.author","Bedke, Jens"],["dc.contributor.author","Bergmann, Lothar"],["dc.date.accessioned","2022-09-01T09:50:50Z"],["dc.date.available","2022-09-01T09:50:50Z"],["dc.date.issued","2022"],["dc.description.abstract","Introduction: Inhibition of neo-angiogenesis is a cornerstone of medical treatment in metastatic renal cell carcinoma (mRCC). While 1st line therapies were previously dominated by inhibitors of the vascular endothelial growth factor axis, 2nd line options were less clearly defined. We investigated the role of everolimus (EVE) or a tyrosine kinase inhibitor (TKI) in 2nd line treatment of mRCC patients. Methods: Key inclusion criteria were measurable mRCC, ECOG 0–1, IMDC risk: good or intermediate and adequate organ function. Patients who progressed on or were intolerant to bevacizumab + interferon were subject for randomization between TKI and EVE treatment. Cross-over occurred at time of progression during 2nd line treatment. Improvement of 2nd line progression-free survival (PFS) rate (PFR) at 6 months from 50% to 65% was the primary endpoint. Secondary endpoints were PFS, total PFS, objective response rate (ORR), overall survival (OS), safety, and patient reported outcomes. Results: In 2012–2015, a total of 22 patients were included. The study was stopped for poor accrual. Ten patients (46%) were randomized to receive 2nd line treatment with EVE (n = 5) or axitinib (n = 4)/sunitinib (n = 1). ECOG 0 was recorded in 20% (EVE) and 60% (TKI). Severe adverse events occurred in approx. 60% in each arm. ORR was 1/5 (20%) for TKI and 0/5 (0%) for EVE. PFR at 6 months was 20% in each arm. Median PFS was 3.7 months (EVE) and 2.2 months (TKI) (hazard ratio [HR] 1.0 [95% confidence interval [CI]: 0.26–3.85]). The OS was comparable between arms HR 1.12 (95% CI: 0.27–4.61). Conclusion: The rapid change of the treatment landscape, the limited use of bevacizumab and interferon in 1st line and the duration of 1st line treatment jeopardized BERAT trial recruitment. The small number of patients is a major limitation of our trial. Our observation indicated the poor prognosis in progressive patients and the limited efficacy of TKI or mTOR inhibitors in 2nd line treatment."],["dc.identifier.doi","10.1159/000522043"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113817"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","jnumed.120.258533"],["dc.bibliographiccitation.journal","Journal of Nuclear Medicine"],["dc.contributor.author","Treiber, Hannes"],["dc.contributor.author","Koenig, Alexander"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Richter, Annika"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-06-01T10:48:40Z"],["dc.date.available","2021-06-01T10:48:40Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.2967/jnumed.120.258533"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86016"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","2159-662X"],["dc.relation.issn","0161-5505"],["dc.title","Liver enzyme elevation after 177 Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]